Biotechnology

Yidu Tech Releases FY2022 ESG Report, Using Socially Beneficial Technology to Drive the Sustainable Development of "Green Healthcare"

HONG KONG, Aug. 3, 2022 /PRNewswire/ -- The digital economy powered by innovative technologies such as artificial intelligence ("AI") and big data has become one of the most powerful drivers of economic growth since the COVID-19 outbreak, in keeping withChina's core strategy of "digitalization, ...

2022-08-03 15:09 2121

Ogawa World Berhad Won the Asia Pacific Enterprise Awards 2022 Malaysia under Inspirational Brand Category

KUALA LUMPUR, Malaysia, Aug. 3, 2022 /PRNewswire/ -- Enterprise Asia, the organizer of the 13th Asia Pacific Enterprise Awards (APEA) 2022 Malaysia, is pleased to recognize 47 exceptional business leaders and enterprises that have played a vital role in shapingMalaysia's entrepreneurial landscape...

2022-08-03 13:14 3137

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. *  ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...

2022-08-03 08:30 2090

Sanyou Biopharmaceuticals Closed the Series B+ Financing Round of Tens of Millions of RMB Led by Huatai Zijin

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. announced that it has closed the Series B+ financing round of tens of millions of RMB. In this round of financing led by Zijin Hongyun Fund and Huatai Guoxin Fund under Huatai Zijin, Sanyou also received follow-on investme...

2022-08-03 08:00 1733

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...

2022-08-02 22:49 3150

GenKOre develops hypercompact base editing system

DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage: www.genkore.com ), a biotech start-up in Korea, had a study on the development of hypercompact adenine base editors (ABEs) published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 22:44 2095

Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...

2022-08-02 21:00 1992

Metabolon Awarded ISO 9001:2015 Recertification

ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...

2022-08-02 20:57 1731

CARsgen Appoints Dr. Hua Jiang as Executive Director

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...

2022-08-02 20:50 2155

Sironax Announces Closing of $200 Million Series B Financing

Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases BEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with...

2022-08-02 19:00 2254

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands, Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Na...

2022-08-02 13:00 2454

Advanced Instruments Acquires SAL Scientific, Expertise, and a Range of Cell Growth Supplements in Support of Research & Drug Discovery Workflows

NORWOOD, Mass., Aug. 2, 2022 /PRNewswire/ -- Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the acquisition of SAL Scientific Ltd., a private company that develops and manufactures a portfolio of cell growth supplements for C...

2022-08-02 10:28 2137

GenKOre develops hypercompact adenine base editors (ABEs)

DAEJEON, South Korea, Aug. 2, 2022 /PRNewswire/ -- GenKOre, a biotech start-up in Korea, succeeded in the development of ABEs based on its own hypercompact gene-editing technology and had the relevant study published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 09:07 2298

Novel and fast typing method developed to control monkeypox by Molecular Biology Systems (MBS) in collaboration with the Amsterdam UMC and Danish Rigshospitalet

GOES, Netherlands, Aug. 2, 2022 /PRNewswire/ -- In the worldwide effort to control monkeypox, a novel and fast typing method to trace monkeypox virus strains was developed by Dutch company Molecular Biology Systems (MBS) in collaboration with the department of Medical Microbiology & Infectious Di...

2022-08-02 08:00 2245

Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in theAsia Pacific (APAC) Operating Region, including progress in the major marke...

2022-08-02 06:54 2136

"OpenDEL®3.0 - DRUG DISCOVERY PARTNER" webinar offered by HitGen and Endpoints News coming up on Thursday 4th August

CHENGDU, China, Aug. 1, 2022 /PRNewswire/ -- "OpenDEL®3.0 – DRUG DISCOVERY PARTNER" webinar will be jointly held by HitGen Inc. and Endpoints News on Thursday 4th August, to present you with a high-quality DEL product with all DEL information sharing and technical support. Dr. Guansai Liu, Execut...

2022-08-01 22:00 1957

Yunji's Technology-empowered Private Label SUYE Celebrates Its 12th Anniversary

HANGZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced the celebration of its private-label skin care brand SUYE's 12th anniversary. SUYE generated over21 million RMB sales of its hig...

2022-08-01 21:00 2704

GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine

* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities * Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months * GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commer...

2022-08-01 21:00 2266

Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical compa...

2022-08-01 20:00 1928

Eccogene Announces US IND Approval for THRβ agonist ECC4703

SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerabilit...

2022-08-01 15:00 1547
1 ... 160161162163164165166 ... 307